Elliott Investment Management has built a significant position in Bio-Rad Laboratories as part of a renewed push into the life sciences sector, according to a report by Bloomberg citing unnamed people familiar with the matter.
The activist investor, which manages roughly $80bn in assets, is aiming to support a recovery in Bio-Rad’s share price following a prolonged period of weakness. The stock has fallen more than 70% from its peak in late 2021, leaving the company valued at around $6.7bn.
While the exact size of Elliott’s holding has not been disclosed, the position is described as sizeable, consistent with the firm’s typical activist approach of building meaningful stakes to influence strategy and valuation outcomes.
The move adds to Elliott’s broader exposure across healthcare and life sciences, an area where the firm has been steadily increasing its activity. It also holds a significant position in Sartorius AG, a key supplier to biologic drug manufacturers and a company with indirect links to Bio-Rad’s ecosystem through its industry exposure.
Bio-Rad itself also maintains a stake in Sartorius, valued at around $5bn, underscoring the interconnected nature of the sector’s corporate and investment relationships.
More recently, Elliott has also backed Charles River Laboratories, continuing its focus on companies tied to drug development, testing, and broader pharmaceutical research infrastructure.
